Unlocking The Potential of KIF22: A Protein Target for Various Diseases

Target Name: KIF22

NCBI ID: G3835

KIF22

Unlocking The Potential of KIF22: A Protein Target for Various Diseases

KIF22 (A-328A3.2), a protein found in various tissues including the brain, heart, and kidneys, has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

KIF22 is a member of the KLF1 (Kirsten) gene family, which is known for its role in regulating gene expression and cell signaling. The KLF1 gene has four known splice variants, KIF21.2, KIF21.1, KIF21.3, and KIF21.4, each with a different splice site. KIF22 is a splicing variant of KIF21.4, and its unique amino acid sequence has led to its unique structure and function.

KIF22 is a 22-kDa protein that contains 10 known protein domains, including a N-terminal transmembrane domain, a T-loop domain, a domain responsible for interacts with DNA, a domain involved in protein-protein interactions, and a C-terminal T-loop domain. The protein is expressed in various tissues and has been shown to play a role in various physiological processes, including cell signaling, inflammation, and fibrosis.

One of the most promising aspects of KIF22 is its potential as a drug target. Its unique structure and function make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its activity. KIF22 has been shown to interact with various molecules, including tyrosine kinase, NF-kappa-B, and TGF-β. It has also been shown to play a role in various signaling pathways, including the TGF-β pathway, which is involved in cell signaling and growth.

In addition to its potential as a drug target, KIF22 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be elevated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. It has also been shown to have potential as a diagnostic biomarker for some of these diseases, such as cancer.

KIF22 has also been shown to have potential as a therapeutic agent in various diseases. Its unique structure and function make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its activity. For example, researchers have shown that KIF22 can be downregulated by small molecules, such as inhibitors of tyrosine kinase or NF-kappa-B, which can reduce its activity and potentially lead to the inhibition of cell signaling pathways.

In addition to its potential as a therapeutic agent, KIF22 has also been shown to have potential as a biomarker for various diseases. Its expression has been shown to be elevated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. It has also been shown to have potential as a diagnostic biomarker for some of these diseases, such as cancer.

In conclusion, KIF22 is a unique protein that has the potential to be a drug target or biomarker for various diseases. Its unique structure and function make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its activity. Its potential as a drug target is further supported by its interaction with various molecules, including tyrosine kinase, NF-kappa-B, and TGF-β, as well as its role in various signaling pathways. Its potential as a biomarker is further supported by its expression being shown to be elevated in various diseases and its potential as a diagnostic biomarker for some of these diseases. Further research is needed to fully understand the role of KIF22 in

Protein Name: Kinesin Family Member 22

Functions: Kinesin family member that is involved in spindle formation and the movements of chromosomes during mitosis and meiosis. Binds to microtubules and to DNA (By similarity). Plays a role in congression of laterally attached chromosomes in NDC80-depleted cells (PubMed:25743205)

The "KIF22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets